G-SPECT nominated for Accenture Innovation Award

G-SPECT nominated for Accenture Innovation Award

See us at WMIC 2017 in Philadelphia, PA – Booth 302
September 13-16

Diagnosing viral infection and treatment response with high-resolution whole-body MILabs PET/CT

Summary

• Image the whole-body of mice at sub-mm PET resolution in order to quantify 18F-FDG uptake in foci in the abdomen, including the S.Int., L.Int., spleen, and mesentery. 
• Monitor DENV-mediated inflammation in vivo and assess the efficacy of novel therapeutic compounds that can directly target the major tissues involved in dengue pathogenesis. 
• Demonstrate for the first time that the quantifiable reduction in intestinal 18F-FDG uptake by PET/CT imaging can be used to non-invasively and robustly define inflammation reduction as a surrogate endpoint for drug efficacy during preclinical development and clinical validation. 
• Show a significant temporal trend in 18F-FDG uptake in intestines and selected tissues and that sub-mm resolution PET robustly differentiated treatment-naive groups from drug-treated infected mouse groups. 
• Illustrate that high resolution whole-body PET/CT imaging of 18F-FDG may have a profound effect on reducing the high costs of drug discovery for emerging infectious diseases through reducing trial size and fast tracking of the drug development process.

Related Publications
1. Guzman MG, Harris E. Dengue. Lancet. 2015; 385(9966):453–465.
2. Sung C, et al. Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. PLoS Negl Trop Dis. 2016;10(8): e0004851.